Amine derivatives, processes for producing them and a use of the

Details Amine derivatives, processes for producing them and a use of the Amine derivatives, processes for producing them and a use of the

1997-05-27

2000-05-02

Richter, Johann

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514428, 514429, 514603, 514620, 5483401, 548561, 558412, 558413, 564 99, 564161, 564305, 564341, 564353, 564369, 564354, 564371, 564372, 564374, 564384, 564389, 564391, C07D23361, C07C25534, C07C21528

Patent

active

060573589

DESCRIPTION:

BRIEF SUMMARY
TECHNICAL FIELD

This invention relates to amine derivatives useful as antiarrhythmic drugs. More specifically, the invention relates to amine derivatives of the following general formula (I) which have a potassium channel blocking action to be useful as, for example, antiarrhythmic drugs and salts thereof: ##STR2## (wherein) A denotes the general formula --(CH.sub.2).sub.m --, --(CH.sub.2).sub.m --O--, --(CH.sub.2).sub.m --NH-- or --(CH.sub.2).sub.m --SO.sub.2 --, where a hydrogen atom in the --(CH.sub.2).sub.m -- moiety may be substituted by one or more hydroxyl groups; --(CH.sub.2).sub.n -- or --CONH--(CH.sub.2).sub.n --; atom, a halogen atom, a cyano group, a lower alkyl group, a lower alkoxy group, a lower alkanoyl group, a nitro group, a hydroxyl group, a lower alkylsulfonyloxy group, a phenoxymethyl group, a heterocyclic group or the group of the general formula --NR.sub.5 R.sub.6, where R.sub.5 and R.sub.6 denote each independently a hydrogen atom, a lower alkanoyl group, a lower alkyl group or a heterocyclic group; atom, a lower alkyl group, a lower alkanoylamino group or a lower alkylamino group; or, alternatively, when R.sub.8a is a hydrogen atom, R.sub.8b denotes a lower alkylsulfonylamino group or a halogen atom (provided that when R.sub.8a is a hydrogen atom and R.sub.8b is a lower alkylsulfonylamino group, R.sub.1 denotes a group of the general formula --NR.sub.5 R.sub.6 or a heterocyclic group); group, a cyano group or a heterocyclic group, where R.sub.10 and R.sub.11 , denote each independently a hydrogen atom or a lower alkylsulfonyl group;
The invention also embraces processes for producing the amine derivatives of the general formula (I) set forth above and salts thereof, as well as a use of them as antiarrhythmic drugs.


TECHNICAL BACKGROUND

Potassium channels which are one of the mechanisms that control systemic physiological actions are distributed in systemic cellular systems including pancreatic .beta.-cells and cardiac muscle and, therefore, drugs that have pharmacological actions to control potassium channels are currently used in the treatment of various circulatory diseases as, for example, antidiabetic drugs, antiarrhythmic drugs, etc. A number of compounds are known in the prior art as such potassium channel blockers. For example, glybenclamide which is an oral antidiabetic drug that blocks potassium channels in pancreatic .beta.-cells has been reported to block ATP-dependent potassium channels in pancreatic .beta.-cells and thereby induce insulin release, hence exhibiting a hypoglycemic action; this action is considered to be a mechanism of action common to oral antidiabetic drugs having the basic structure of sulfonylureas as the skeleton. In this connection, 4-substituted benzoic acid derivatives are known to have the same action as reported in two reference, European Journal of Pharmacology, 141, 243-251 (1987) and British Journal of Pharmacology, 93, 61-68 (1988). On the other hand, compounds that block potassium channels in the cardiac muscle have an antiarrhythmic action and, according to Vaughan Williams, they are classified as antiarrhythmic drugs of class III (see Anti-Arrhythmic Action, E. M. Vaughan Williams, Academic Press, 1980). Examples of such compounds have recently been put forward in Japanese Patent Publication No. Hei 3-60814 and European Patent Publication No. 0245997 as antiarrhythmic drugs that are compounds represented by the following general formula (A): ##STR3## R.sup.a is --NO.sub.2, --NH.sub.2 or --NHSO.sub.2 R.sup.1, where R.sup.1 is a C.sub.1 -C.sub.4 alkyl group; (C.sub.1 -C.sub.4 alkyl) or --CONR.sup.4 R.sup.5 ; when taken together with the nitrogen atom to which they are bound, denote a 1-pyrrolidinyl, piperidino, morpholino or N-methylpiperazin-1-yl group, provided that when one of R.sup.a and R.sup.b is --NO.sub.2, the other is not --NH.sub.2 ; optionally substituted by a methyl group;
However, the so far proposed prior art potassium channel blocking antiarrhythmic drugs including the above-described compounds are not necessarily satisfa

REFERENCES:
patent: 4959366 (1990-09-01), Cross et al.
patent: 5079248 (1992-01-01), Cross et al.

Affiliated with

Also associated with

Rating

Amine derivatives, processes for producing them and a use of the does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Amine derivatives, processes for producing them and a use of the, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amine derivatives, processes for producing them and a use of the will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1594297